Imidapril
Alternative Names: Novarok; SH 6366; TA 6366; TanatrilLatest Information Update: 24 Sep 2021
At a glance
- Originator Tanabe Seiyaku
- Developer G.L. Pharma; Gerolymatos Group; Mitsubishi Tanabe Pharma Corporation; Trinity-Chiesi Pharmaceuticals
- Class Antihypertensives; Heart failure therapies; Imidazolidines; Small molecules
- Mechanism of Action ACE inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies; Hypertension
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 03 Aug 2005 Xanodyne Pharmaceuticals has acquired the pharmaceutical assets of aaiPharma
- 15 Feb 2003 Phase-II clinical trials in Hypertension in Canada (PO)